BCKDK deficiency: a treatable neurodevelopmental disease amenable to newborn screening

Imagem de Miniatura
Arquivos
art_TANGERAAS_BCKDK_deficiency_a_treatable_neurodevelopmental_disease_amenable_to_2023.PDF (842.1 KB)
Citações na Scopus
3
Tipo de produção
article
Data de publicação
2023
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
OXFORD UNIV PRESS
Autores
TANGERAAS, Trine
CONSTANTE, Juliana R.
BACKE, Paul Hoff
OYARZABAL, Alfonso
NEUGEBAUER, Julia
WEINHOLD, Natalie
BOEMER, Francois
DEBRAY, Francois G.
OZTURK-HISM, Burcu
EVREN, Gumus
Citação
BRAIN, v.146, n.7, p.3003-3013, 2023
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
There are few causes of treatable neurodevelopmental diseases described to date. Branched-chain ketoacid dehydrogenase kinase (BCKDK) deficiency causes branched-chain amino acid (BCAA) depletion and is linked to a neurodevelopmental disorder characterized by autism, intellectual disability and microcephaly. We report the largest cohort of patients studied, broadening the phenotypic and genotypic spectrum. Moreover, this is the first study to present newborn screening findings and mid-term clinical outcome. In this cross-sectional study, patients with a diagnosis of BCKDK deficiency were recruited via investigators' practices through a MetabERN initiative. Clinical, biochemical and genetic data were collected. Dried blood spot (DBS) newborn screening (NBS) amino acid profiles were retrieved from collaborating centres and compared to a healthy newborn reference population. Twenty-one patients with BCKDK mutations were included from 13 families. Patients were diagnosed between 8 months and 16 years (mean: 5.8 years, 43% female). At diagnosis, BCAA levels (leucine, valine and isoleucine) were below reference values in plasma and in CSF. All patients had global neurodevelopmental delay; 18/21 had gross motor function (GMF) impairment with GMF III or worse in 5/18, 16/16 intellectual disability, 17/17 language impairment, 12/17 autism spectrum disorder, 9/21 epilepsy, 12/15 clumsiness, 3/21 had sensorineural hearing loss and 4/20 feeding difficulties. No microcephaly was observed at birth, but 17/20 developed microcephaly during follow-up. Regression was reported in six patients. Movement disorder was observed in 3/21 patients: hyperkinetic movements (1), truncal ataxia (1) and dystonia (2). After treatment with a high-protein diet (>= 2 g/kg/day) and BCAA supplementation (100-250 mg/kg/day), plasma BCAA increased significantly (P < 0.001), motor functions and head circumference stabilized/improved in 13/13 and in 11/15 patients, respectively. Among cases with follow-up data, none of the three patients starting treatment before 2 years of age developed autism at follow-up. The patient with the earliest age of treatment initiation (8 months) showed normal development at 3 years of age. NBS in DBS identified BCAA levels significantly lower than those of the normal population. This work highlights the potential benefits of dietetic treatment, in particular early introduction of BCAA. Therefore, it is of utmost importance to increase awareness about this treatable disease and consider it as a candidate for early detection by NBS programmes. Tangeraas et al. describe the largest series of BCKDK deficiency patients to date, including responses to dietetic treatment. Early introduction of BCAA ameliorates the BCKDK deficiency phenotype. This treatable neurodevelopmental disease should be considered for inclusion in newborn screening programmes.
Palavras-chave
BCKDK, intellectual disability, autism spectrum disorder, microcephaly, newborn screening
URI
https://observatorio.fm.usp.br/handle/OPI/54948
Referências
  1. American Psychiatric Association, 2013, DIAGN STAT MAN MENT, V5th
  2. [Anonymous], WHO CHILD GROWTH STA
  3. Bateman A, 2015, NUCLEIC ACIDS RES, V43, pD204, DOI 10.1093/nar/gku989
  4. Boemer F, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23042253
  5. Chalmers R.A., 1982, ORGANIC ACIDS MAN AN
  6. Cole JT, 2012, FRONT NEUROANAT, V6, DOI 10.3389/fnana.2012.00018
  7. Elsabbagh M, 2012, AUTISM RES, V5, P160, DOI 10.1002/aur.239
  8. Fernandez C., 2011, ESTUDIO CRECIMIENTO
  9. Garcia-Cazorla A, 2014, HUM MUTAT, V35, P470, DOI 10.1002/humu.22513
  10. Harris RA, 2005, J NUTR, V135, p1527S, DOI 10.1093/jn/135.6.1527S
  11. van Konijnenburg EMMH, 2021, ORPHANET J RARE DIS, V16, DOI 10.1186/s13023-021-01727-2
  12. Kang LJ, 2020, BIOMED CHROMATOGR, V34, DOI 10.1002/bmc.4633
  13. Maple Syrup Urine Disease (Branched-Chain Ketoaciduria), ONLINE METABOLIC MOL
  14. Munoz M., 2010, COMPOSICIO N ALIMENT
  15. Novarino G, 2012, SCIENCE, V338, P394, DOI 10.1126/science.1224631
  16. Palisano R, 1997, DEV MED CHILD NEUROL, V39, P214, DOI 10.1111/j.1469-8749.1997.tb07414.x
  17. Richards S, 2015, GENET MED, V17, P405, DOI 10.1038/gim.2015.30
  18. Rowe AD, 2021, INT J NEONAT SCREEN, V7, DOI 10.3390/ijns7020023
  19. Sanchez Gonzalez E., 2011, AN PEDIATR, V74, p193., DOI 10.1016/J.ANPEDI.2010.10.005
  20. Saudubray JM, 2019, J INHERIT METAB DIS, V42, P706, DOI 10.1002/jimd.12086
  21. Suryawan A, 1998, AM J CLIN NUTR, V68, P72, DOI 10.1093/ajcn/68.1.72
  22. Tabanhoglu D, 2009, PEDIATR DERMATOL, V26, P150, DOI 10.1111/j.1525-1470.2008.00803.x
  23. 2007, WHO TECH REP SER, V935, P1

Coleções
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/63